- Home
- Publications
- Publication Search
- Publication Details
Title
A Potential Role for HUWE1 in Modulating Cisplatin Sensitivity
Authors
Keywords
-
Journal
Cells
Volume 10, Issue 5, Pages 1262
Publisher
MDPI AG
Online
2021-05-20
DOI
10.3390/cells10051262
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours
- (2020) Zuzana Cierna et al. BMC CANCER
- The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer
- (2020) Xiaofeng Gong et al. INVESTIGATIONAL NEW DRUGS
- XPA: DNA Repair Protein of Significant Clinical Importance
- (2020) Lucia Borszéková Pulzová et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
- (2020) Elizabeth K. Lee et al. Cancers
- Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of cisplatin sensitivity in muscle-invasive bladder cancer
- (2020) G Kumar et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens
- (2020) Kristen E. Clements et al. Nature Communications
- Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity
- (2019) Long Cui et al. Journal of Ovarian Research
- Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines
- (2019) Jan J. Bandolik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Enhanced activity of variant DNA polymerase β (D160G) contributes to cisplatin therapy by impeding the efficiency of NER
- (2019) Meina Wang et al. MOLECULAR CANCER RESEARCH
- Norcantharidin inhibits the DDR of bladder cancer stem-like cells through cdc6 degradation
- (2019) Xianghua Shi et al. OncoTargets and Therapy
- MCL-1 inhibitors – where are we now (2019)?
- (2019) Steven Fletcher EXPERT OPINION ON THERAPEUTIC PATENTS
- Precision oncology: lessons learned and challenges for the future
- (2019) Hsih-Te Yang et al. Cancer Management and Research
- EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†
- (2019) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Direct regulation of Chk1 protein stability by E3 ubiquitin ligase HUWE1
- (2019) Katelyn B. Cassidy et al. FEBS Journal
- CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment
- (2019) Hui Xing et al. ACTA PHARMACOLOGICA SINICA
- Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
- (2019) Timothy Gilligan et al. Journal of the National Comprehensive Cancer Network
- CRL4B RBBP7 targets HUWE1 for ubiquitination and proteasomal degradation
- (2018) Fei Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Modulation of Mcl-1 transcription by serum deprivation sensitizes cancer cells to cisplatin
- (2018) Viacheslav V. Senichkin et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- ATR/CHK1 inhibitors and cancer therapy
- (2018) Zhaojun Qiu et al. RADIOTHERAPY AND ONCOLOGY
- HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53
- (2018) Dong Yang et al. Theranostics
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- DNA repair pathways and cisplatin resistance: an intimate relationship
- (2018) CR Rocha et al. Clinics
- Ubiquitin Linkage-Specific Affimers Reveal Insights into K6-Linked Ubiquitin Signaling
- (2017) Martin A. Michel et al. MOLECULAR CELL
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- p53-independent p21 induction by MELK inhibition
- (2017) Tatsuo Matsuda et al. Oncotarget
- A conformational switch regulates the ubiquitin ligase HUWE1
- (2017) Bodo Sander et al. eLife
- HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation
- (2016) Kevin B Myant et al. EMBO Molecular Medicine
- HUWE1 interacts with PCNA to alleviate replication stress
- (2016) Katherine N Choe et al. EMBO REPORTS
- Tumour suppressive function of HUWE1 in thyroid cancer
- (2016) Weiyuan Ma et al. JOURNAL OF BIOSCIENCES
- Activation of the ATR kinase by the RPA-binding protein ETAA1
- (2016) Peter Haahr et al. NATURE CELL BIOLOGY
- HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
- (2016) N Stojanovic et al. ONCOGENE
- Bax/Bak activation in the absence of Bid, Bim, Puma and p53
- (2016) J Zhang et al. Cell Death & Disease
- Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells
- (2016) Sansan Chen et al. Oncotarget
- Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
- (2016) Samer Alzoubi et al. Oncotarget
- Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
- (2016) Maryam Zanjirband et al. Oncotarget
- The HECT domain ubiquitin ligase HUWE1 targets unassembled soluble proteins for degradation
- (2016) Yue Xu et al. Cell Discovery
- Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy
- (2015) Lin-run Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ATM and ATR signaling at a glance
- (2015) P. Awasthi et al. JOURNAL OF CELL SCIENCE
- Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
- (2015) Xi-Chun Hu et al. LANCET ONCOLOGY
- Broad targeting of resistance to apoptosis in cancer
- (2015) Ramzi M. Mohammad et al. SEMINARS IN CANCER BIOLOGY
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer
- (2015) Rui Huang et al. Oncotarget
- The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
- (2015) Christophe Deben et al. Oncotarget
- HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin–proteasome pathway
- (2014) Xiaozhen Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Coupling of Human DNA Excision Repair and the DNA Damage Checkpoint in a Definedin VitroSystem
- (2014) Laura A. Lindsey-Boltz et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TCRP1 contributes to cisplatin resistance by preventing Pol β degradation in lung cancer cells
- (2014) Xiaorong Liu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Frequencies of mutagenic translesion DNA synthesis over cisplatin-guanine intra-strand crosslinks in lacZ plasmids propagated in human cells
- (2014) Yoshihiro Fujikawa et al. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
- High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells
- (2014) Yuexin Zhou et al. NATURE
- Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy
- (2014) Pinki Chowdhury et al. Nature Communications
- HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase β
- (2014) Qingming Fang et al. Nature Communications
- Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
- (2013) J Mendoza et al. BRITISH JOURNAL OF CANCER
- Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9
- (2013) Jacqueline L.Y. Chee et al. CELL CYCLE
- Roles of Chk1 in cell biology and cancer therapy
- (2013) Youwei Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity
- (2013) Anbarasi Kothandapani et al. NUCLEIC ACIDS RESEARCH
- Two 4N Cell-Cycle Arrests Contribute to Cisplatin-Resistance
- (2013) Hong Shen et al. PLoS One
- Chromatin Compaction Protects Genomic DNA from Radiation Damage
- (2013) Hideaki Takata et al. PLoS One
- Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions
- (2013) Rossella Marullo et al. PLoS One
- Candidate tumor suppressor BTG3 maintains genomic stability by promoting Lys63-linked ubiquitination and activation of the checkpoint kinase CHK1
- (2013) Y.-C. Cheng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- On the Discovery, Biological Effects, and Use of Cisplatin and Metallocenes in Anticancer Chemotherapy
- (2012) Santiago Gómez-Ruiz et al. BIOINORGANIC CHEMISTRY AND APPLICATIONS
- DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
- (2012) Wynand P. Roos et al. CANCER LETTERS
- Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent
- (2012) Alessandra di Pietro et al. CELL CYCLE
- Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF and p53 in MYC-Driven B Cell Neoplasms
- (2012) Chen-Feng Qi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The E3 ubiquitin ligase Mule acts through the ATM–p53 axis to maintain B lymphocyte homeostasis
- (2012) Zhenyue Hao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Structural basis for cisplatin DNA damage tolerance by human polymerase η during cancer chemotherapy
- (2012) Ajay Ummat et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Coordinated regulation of XPA stability by ATR and HERC2 during nucleotide excision repair
- (2012) T-H Lee et al. ONCOGENE
- Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 Interaction
- (2012) Khaled H. Barakat et al. PLoS One
- Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase Mule increases the stability of Mcl-1 in breast cancer cells
- (2011) S Pervin et al. BRITISH JOURNAL OF CANCER
- Translesion DNA synthesis in the context of cancer research
- (2011) Philip A Knobel et al. Cancer Cell International
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2
- (2011) J. Zhang et al. GENES & DEVELOPMENT
- Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells
- (2011) Mingmei Liao et al. Molecular Cancer
- The spatial and temporal organization of ubiquitin networks
- (2011) Caroline Grabbe et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- Regulation of oxidative DNA damage repair by DNA polymerase and MutYH by cross-talk of phosphorylation and ubiquitination
- (2011) E. Markkanen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- C-terminal UBA domains protect ubiquitin receptors by preventing initiation of protein degradation
- (2011) Christian Heinen et al. Nature Communications
- HERC2 Is an E3 Ligase That Targets BRCA1 for Degradation
- (2010) W. Wu et al. CANCER RESEARCH
- New insights into p53 activation
- (2010) Christopher L Brooks et al. CELL RESEARCH
- Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts
- (2010) P. Ji et al. HAEMATOLOGICA
- CDC6 interaction with ATR regulates activation of a replication checkpoint in higher eukaryotic cells
- (2010) K. Yoshida et al. JOURNAL OF CELL SCIENCE
- Ubiquitin-Independent Degradation of Antiapoptotic MCL-1
- (2010) D. P. Stewart et al. MOLECULAR AND CELLULAR BIOLOGY
- Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression
- (2010) Svetlana Usanova et al. Molecular Cancer
- Homologous Recombination Restarts Blocked Replication Forks at the Expense of Genome Rearrangements by Template Exchange
- (2010) Sarah Lambert et al. MOLECULAR CELL
- Reconstitution of RPA-covered single-stranded DNA-activated ATR-Chk1 signaling
- (2010) J.-H. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- DDB1 Targets Chk1 to the Cul4 E3 Ligase Complex in Normal Cycling Cells and in Cells Experiencing Replication Stress
- (2009) V. Leung-Pineda et al. CANCER RESEARCH
- Ubiquitin ligase ARF-BP1/Mule modulates base excision repair
- (2009) Jason L Parsons et al. EMBO JOURNAL
- BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells
- (2009) Moltira Promkan et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor Suppressive Functions of p53
- (2009) J. T. Zilfou et al. Cold Spring Harbor Perspectives in Biology
- Acetylation Is Indispensable for p53 Activation
- (2008) Yi Tang et al. CELL
- Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1
- (2008) Steffi Herold et al. EMBO JOURNAL
- TopBP1 activates ATR through ATRIP and a PIKK regulatory domain
- (2008) D. A. Mordes et al. GENES & DEVELOPMENT
- p53 Oligomerization Is Essential for Its C-terminal Lysine Acetylation
- (2008) Yoko Itahana et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cdt1 and Cdc6 Are Destabilized by Rereplication-induced DNA Damage
- (2008) Jonathan R. Hall et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More